These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28154920)

  • 1. High-grade serous ovarian cancer: the clone wars.
    Salomon-Perzyński A; Salomon-Perzyńska M; Michalski B; Skrzypulec-Plinta V
    Arch Gynecol Obstet; 2017 Mar; 295(3):569-576. PubMed ID: 28154920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
    Voutsadakis IA
    Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
    BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
    Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
    J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redefining the standard of care for low-grade serous ovarian cancer.
    Manning-Geist BL; Cantor T; O'Cearbhaill RE; Grisham RN
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):205-226. PubMed ID: 38805312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in precision therapy of low-grade serous ovarian cancer: A review.
    Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
    Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clonal evolution of metastases from primary serous epithelial ovarian cancers.
    Khalique L; Ayhan A; Whittaker JC; Singh N; Jacobs IJ; Gayther SA; Ramus SJ
    Int J Cancer; 2009 Apr; 124(7):1579-86. PubMed ID: 19123469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer.
    El-Arabey AA; Abdalla M; Abd-Allah AR
    Hum Cell; 2020 Jul; 33(3):904-906. PubMed ID: 32388811
    [No Abstract]   [Full Text] [Related]  

  • 12. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    Lisio MA; Fu L; Goyeneche A; Gao ZH; Telleria C
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.
    McPherson A; Roth A; Laks E; Masud T; Bashashati A; Zhang AW; Ha G; Biele J; Yap D; Wan A; Prentice LM; Khattra J; Smith MA; Nielsen CB; Mullaly SC; Kalloger S; Karnezis A; Shumansky K; Siu C; Rosner J; Chan HL; Ho J; Melnyk N; Senz J; Yang W; Moore R; Mungall AJ; Marra MA; Bouchard-Côté A; Gilks CB; Huntsman DG; McAlpine JN; Aparicio S; Shah SP
    Nat Genet; 2016 Jul; 48(7):758-67. PubMed ID: 27182968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomics and molecular mechanisms of high grade serous ovarian cancer: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Rankin EB
    Int J Gynecol Cancer; 2019 Aug; 29(Suppl 2):s7-s11. PubMed ID: 31462542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
    Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
    Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.
    Gourley C; Farley J; Provencher DM; Pignata S; Mileshkin L; Harter P; Maenpaa J; Kim JW; Pujaide-Lauraine E; Glasspool RM; Ray-Coquard I; Gershenson D
    Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S9-13. PubMed ID: 25341587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
    Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
    Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.